Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy vs. cytoreductive surgery alone for intrahepatic cholangiocarcinoma with peritoneal metastases: A retrospective cohort study

被引：10
作者：
Feng, Feiling [1 ]
Gao, Qingxiang [1 ]
Wu, Yue [1 ]
Liu, Chen [1 ]
Yu, Yong [1 ]
Li, Bin [1 ]
Chu, Kaijian [1 ]
Yi, Bin [1 ]
Cheng, Qingbao [1 ]
Jiang, Xiaoqing [1 ]
机构：
[1] Eastern Hepatobiliary Surg Hosp, Dept Biliary Tract 1, 225 Changhai Rd, Shanghai 200433, Peoples R China
来源：
EJSO | 2021年 / 47卷 / 09期
关键词：
Intrahepatic cholangiocarcinoma; Cytoreductive surgery; Survival; Prognosis; Hyperthermic intraperitoneal chemotherapy; DIGESTIVE-TRACT CANCER; RADIOFREQUENCY ABLATION; PERFUSION CHEMOTHERAPY; BLADDER-CANCER; BILIARY; HIPEC; CHEMOHYPERTHERMIA; CARCINOMATOSIS; SURVIVAL; THERAPY;
D O I：
10.1016/j.ejso.2021.05.014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has survival benefits in patients with intraperitoneal malignant lesions, but there is no study specific to intrahepatic cholangiocarcinoma (ICC). Purpose: To compare the prognosis of patients with advanced ICC undergoing CRS + HIPEC compared with CRS alone. Methods: This study was a retrospective cohort study of patients with advanced ICC treated at the Shanghai Eastern Hepatobiliary Surgery Hospital between 01/2014 and 12/2018. The patients were divided into either CRS + HIPEC or CRS group based on the treatment they received. Overall survival (OS), complications, hospital stay, biochemical indicators, tumor markers, and number of HIPEC were examined. Results: There were 51 and 61 patients in the CRS + HIPEC and CRS groups, respectively. There were no differences between the groups regarding preoperative CA19-9 levels (421 +/- 381 vs. 523 +/- 543 U/mL, P = 0.208). The hospital stay was longer in the CRS + HIPEC group (22.2 +/- 10.0 vs. 18.6 +/- 7.6 days, P = 0.033). The occurrence of overall complications was similar in the two groups (37.2% vs. 34.4%, P = 0.756). The postoperative CA19-9 levels were lower in the CRS + HIPEC group compared with the CRS group (196 +/- 320 vs. 337 +/- 396 U/mL, P = 0.044). The median OS was longer in the CRS + HIPEC group than in the CRS group (25.53 vs. 11.17 months, P < 0.001). Compared with the CRS group, the CRS + HIPEC group showed a higher occurrence of leukopenia (7.8% vs. 0, P = 0.040) but a lower occurrence of total bilirubin elevation (15.7% vs. 37.7%, P = 0.032). Conclusion: CRS + HIPEC could be a treatment option for patients with advanced ICC, with improved OS and similar complications and adverse events compared with CRS alone. (c) 2021 Published by Elsevier Ltd.
引用
收藏
页码：2363 / 2368
页数：6
相关论文
共 47 条
[1]   Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups [J].
Amblard, I ;
Mercier, F. ;
Bartlett, D. L. ;
Ahrendt, S. A. ;
Lee, K. W. ;
Zeh, H. J. ;
Levine, E. A. ;
Baratti, D. ;
Deraco, M. ;
Piso, P. ;
Morris, D. L. ;
Rau, B. ;
Tentes, A. A. K. ;
Tuech, J-J ;
Quenet, F. ;
Akaishi, E. ;
Pocard, M. ;
Yonemura, Y. ;
Lorimier, G. ;
Delroeux, D. ;
Villeneuve, L. ;
Glehen, O. ;
Passot, G. .
EJSO, 2018, 44 (09) :1378-1383
[2]  
Andr ~e T, 2019, CANC COLON NONMETAST
[3]   Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study [J].
Ba, Mingchen ;
Cui, Shuzhong ;
Long, Hui ;
Gong, Yuanfeng ;
Wu, Yinbing ;
Lin, Kunpeng ;
Tu, Yinuo ;
Zhang, Bahuo ;
Wu, Wanbo .
BMC UROLOGY, 2019, 19 (01)
[4]   Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection [J].
Ba, Mingchen ;
Cui, Shuzhong ;
Wang, Bin ;
Long, Hui ;
Yan, Zhaofei ;
Wang, Shuai ;
Wu, Yinbing ;
Gong, Yuanfeng .
ONCOLOGY REPORTS, 2017, 37 (05) :2761-2770
[5]  
Beaujard AC, 2000, CANCER-AM CANCER SOC, V88, P2512, DOI 10.1002/1097-0142(20000601)88:11<2512::AID-CNCR12>3.0.CO
[6]  
2-J
[7]  
Brandl A, 2017, ANN MED SURG, V22, P7, DOI 10.1016/j.amsu.2017.08.009
[8]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[9]   The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI) [J].
Bushati, M. ;
Rovers, K. P. ;
Sommariva, A. ;
Sugarbaker, P. H. ;
Morris, D. L. ;
Yonemura, Y. ;
Quadros, C. A. ;
Somashekhar, S. P. ;
Ceelen, W. ;
Dube, P. ;
Li, Y. ;
Verwaal, V. J. ;
Glehen, O. ;
Piso, P. ;
Spiliotis, J. ;
Teo, M. C. C. ;
Gonzalez-Moreno, S. ;
Cashin, P. H. ;
Lehmann, K. ;
Deraco, M. ;
Moran, B. ;
de Hingh, I. H. J. T. .
EJSO, 2018, 44 (12) :1942-1948
[10]   Radiofrequency Ablation of Intrahepatic Cholangiocarcinoma: Preliminary Experience [J].
Carrafiello, Gianpaolo ;
Lagana, Domenico ;
Cotta, Elisa ;
Mangini, Monica ;
Fontana, Federico ;
Bandiera, Francesca ;
Fugazzola, Carlo .
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2010, 33 (04) :835-839
12345